Latest Regulatory Approvals News

BetMakers Technology Group reports solid Q3 FY25 financial gains alongside a strategic binding agreement to acquire Nevada’s LVDC, expanding its global racing technology footprint.

BetMakers Technology Group is poised to expand its North American footprint by acquiring LVDC, Nevada’s exclusive pari-mutuel wagering provider, targeting an initial A$4 million in annual revenue.

Metals X Limited has announced a pre-conditional voluntary cash partial offer to acquire up to 28% of Greentech Technology International Limited at HK$0.35 per share, aiming to increase its stake in the joint venture behind the Renison Tin Mine. The offer follows Greentech's failure to meet pre-conditions for a full takeover and comes amid ongoing trading suspension and delayed financial results.

PointsBet has secured a significantly improved acquisition proposal from MIXI, lifting the cash offer by 13.2% to $1.20 per share and postponing the shareholder vote to June 25. The move intensifies the takeover battle amid ongoing regulatory approvals and a rival bid from Betr Entertainment.

Asra Minerals Limited has launched a substantial options offer linked to a recent $3 million placement, aiming to enhance liquidity and satisfy obligations under the placement. The company plans to list these options on the ASX by the end of June 2025.

Manuka Resources is poised to restart silver production at its Wonawinta Mine targeting 13.2 million ounces, while progressing its large-scale vanadium-titanium-magnetite project in New Zealand with a robust $1.26 billion valuation.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Western Yilgarn NL has secured the Cardea 3 Bauxite Project in Western Australia's Darling Range, adding a significant high-grade bauxite asset near its Julimar Project. Historical drilling confirms strong alumina grades and strategic infrastructure access.

Titanium Sands Limited has locked in a $600,000 convertible loan facility from major shareholders to fund environmental studies and progress its Mannar Heavy Mineral Project. This funding milestone follows recent regulatory approvals and marks a critical step forward for the company.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

James Hardie Industries has successfully syndicated $3.5 billion in new credit facilities, providing robust financial backing for its planned merger with The AZEK Company Inc. This move significantly reduces prior bridge loan commitments and enhances the company’s financial flexibility.